HAL (France)open access
Neoadjuvant pembrolizumab with a watch‑and‑wait strategy for localized MSI/dMMR colon cancer: Study protocol for a randomized GERCOR 109 – PRODIGE 84 phase II trial (PREMICES)
Pathological complete response, Early-stage colon cancer, Organ preservation, 1, Major pathological response, 0, Neoadjuvant immunotherapy, 2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 159268
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.